NYSE:NVRO Nevro (NVRO) Stock Price, News & Analysis → Things Are Not Normal in America – Here’s What to Do (From Stansberry Research) (Ad) Free NVRO Stock Alerts $10.51 +0.35 (+3.44%) (As of 04:10 PM ET) Add Compare Share Share Today's Range$10.02▼$10.6250-Day Range$10.17▼$15.3152-Week Range$10.02▼$28.89Volume586,687 shsAverage Volume505,025 shsMarket Capitalization$385.52 millionP/E RatioN/ADividend YieldN/APrice Target$20.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Nevro alerts: Email Address Nevro MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside91.0% Upside$20.00 Price TargetShort InterestBearish12.05% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.20Based on 17 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.54) to ($2.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.38 out of 5 starsMedical Sector480th out of 915 stocksSurgical & Medical Instruments Industry60th out of 96 stocks 4.0 Analyst's Opinion Consensus RatingNevro has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 11 hold ratings, and 1 sell rating.Amount of Analyst CoverageNevro has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nevro's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.05% of the float of Nevro has been sold short.Short Interest Ratio / Days to CoverNevro has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Nevro has recently decreased by 0.71%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldNevro does not currently pay a dividend.Dividend GrowthNevro does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NVRO. Previous Next 1.8 News and Social Media Coverage News SentimentNevro has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Nevro this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for NVRO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nevro insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.20% of the stock of Nevro is held by insiders.Percentage Held by Institutions95.52% of the stock of Nevro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nevro's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nevro are expected to grow in the coming year, from ($2.54) to ($2.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nevro is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nevro is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNevro has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nevro's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Nevro Stock (NYSE:NVRO)Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.Read More NVRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVRO Stock News HeadlinesMay 9, 2024 | prnewswire.comNevro to Present at BofA Securities 2024 Healthcare ConferenceMay 8, 2024 | markets.businessinsider.comAssessing Nevro: Insights From 9 Financial AnalystsMay 9, 2024 | InvestorPlace (Ad)Proof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…May 8, 2024 | markets.businessinsider.comHold Rating on Nevro Corp Amidst Strong Q1 Performance and Conservative OutlookMay 8, 2024 | finance.yahoo.comNevro Corp. (NYSE:NVRO) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comNevro Corp (NVRO) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of Financial ...May 7, 2024 | prnewswire.comNevro Reports First-Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comNevro earnings preview: what Wall Street is expectingMay 9, 2024 | InvestorPlace (Ad)Proof that the Musk/Bezos rivalry is about to hit a new levelElon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats…May 7, 2024 | americanbankingnews.comNevro Corp. (NYSE:NVRO) Receives Average Rating of "Hold" from AnalystsMay 5, 2024 | americanbankingnews.comNevro (NVRO) Scheduled to Post Quarterly Earnings on TuesdayApril 17, 2024 | finance.yahoo.comNevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024April 17, 2024 | prnewswire.comNevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024April 3, 2024 | benzinga.comWhere Nevro Stands With AnalystsMarch 25, 2024 | finanznachrichten.deEnviroGold Global Limited: NVRO announces Management Changes and provides an update on its Proprietary Leaching Technology CommercializationMarch 11, 2024 | finance.yahoo.comNVRO Mar 2024 20.000 putFebruary 28, 2024 | prnewswire.comNevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral ScrewFebruary 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)February 26, 2024 | markets.businessinsider.comNevro Corp: Hold Rating Affirmed Amidst Mixed Performance and Market UncertaintyFebruary 23, 2024 | realmoney.thestreet.comNevro just downgraded at Oppenheimer, here's whyFebruary 22, 2024 | finanznachrichten.deNevro Corp.: Nevro Reports Fourth-Quarter and Full-Year 2023 Financial ResultsFebruary 22, 2024 | fool.comWhy Nevro Stock Lagged the Market on ThursdayFebruary 22, 2024 | markets.businessinsider.comHold Rating on Nevro Corp Amid Modest Growth and Cautious 2024 OutlookFebruary 22, 2024 | markets.businessinsider.comAnalyst Scoreboard: 4 Ratings For NevroFebruary 22, 2024 | finance.yahoo.comNevro Corp. (NYSE:NVRO) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | washingtonpost.comNevro: Q4 Earnings SnapshotFebruary 21, 2024 | msn.comNevro GAAP EPS of -$0.25 beats by $0.24, revenue of $116.17M beats by $0.17MSee More Headlines Receive NVRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today5/09/2024Next Earnings (Estimated)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:NVRO CUSIPN/A CIK1444380 Webwww.nevro.com Phone(650) 251-0005FaxN/AEmployees1,215Year FoundedN/APrice Target and Rating Average Stock Price Target$20.00 High Stock Price Target$40.00 Low Stock Price Target$11.00 Potential Upside/Downside+90.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,210,000.00 Net Margins-21.69% Pretax Margin-23.02% Return on Equity-30.22% Return on Assets-15.17% Debt Debt-to-Equity Ratio0.72 Current Ratio6.37 Quick Ratio4.94 Sales & Book Value Annual Sales$425.17 million Price / Sales0.91 Cash FlowN/A Price / Cash FlowN/A Book Value$8.10 per share Price / Book1.30Miscellaneous Outstanding Shares36,681,000Free Float35,507,000Market Cap$385.52 million OptionableOptionable Beta0.96 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Kevin R. Thornal (Age 50)President, CEO & Director Comp: $1.37MMr. Roderick H. MacLeod (Age 57)Senior VP & CFO Comp: $653.1kMr. Kashif Rashid (Age 50)Senior VP of Corporate Development & Chief Legal Officer Comp: $629.62kMr. Greg Siller (Age 43)Senior VP & Chief Commercial Officer Comp: $419.9kMr. Richard B. Carter (Age 53)Chief Accounting Officer Mr. Christofer Christoforou (Age 54)Senior Vice President of Technical Operations Comp: $367.4kGeeta KavetiVP and Chief Compliance & Privacy OfficerMeredith VornholtVice President of Global MarketingMs. Shana D. Ross M.B.A. (Age 51)Senior VP & Chief Human Resources Officer Dr. David Caraway M.D. (Age 67)Ph.D., Senior VP & Chief Medical Officer More ExecutivesKey CompetitorsOraSure TechnologiesNASDAQ:OSURPulse BiosciencesNASDAQ:PLSEBeauty HealthNASDAQ:SKINAnika TherapeuticsNASDAQ:ANIKBioventusNYSE:BVSView All CompetitorsInsiders & InstitutionsBlair William & Co. ILBought 13,750 shares on 5/9/2024Ownership: 0.142%State Board of Administration of Florida Retirement SystemBought 1,430 shares on 5/9/2024Ownership: 0.032%Susquehanna Fundamental Investments LLCBought 100,116 shares on 5/7/2024Ownership: 0.273%Swiss National BankSold 6,800 shares on 5/7/2024Ownership: 0.176%Oppenheimer Asset Management Inc.Bought 9,586 shares on 5/7/2024Ownership: 0.084%View All Insider TransactionsView All Institutional Transactions NVRO Stock Analysis - Frequently Asked Questions Should I buy or sell Nevro stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 1 sell rating, 11 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares. View NVRO analyst ratings or view top-rated stocks. What is Nevro's stock price target for 2024? 13 brokerages have issued 1-year price objectives for Nevro's shares. Their NVRO share price targets range from $11.00 to $40.00. On average, they anticipate the company's share price to reach $20.00 in the next twelve months. This suggests a possible upside of 91.0% from the stock's current price. View analysts price targets for NVRO or view top-rated stocks among Wall Street analysts. How have NVRO shares performed in 2024? Nevro's stock was trading at $21.52 at the beginning of the year. Since then, NVRO stock has decreased by 51.3% and is now trading at $10.47. View the best growth stocks for 2024 here. When is Nevro's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024. View our NVRO earnings forecast. How were Nevro's earnings last quarter? Nevro Corp. (NYSE:NVRO) issued its quarterly earnings data on Tuesday, May, 7th. The medical equipment provider reported ($0.70) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.32. The medical equipment provider earned $101.90 million during the quarter, compared to the consensus estimate of $97.90 million. Nevro had a negative net margin of 21.69% and a negative trailing twelve-month return on equity of 30.22%. Nevro's revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.98) earnings per share. What ETFs hold Nevro's stock? ETFs with the largest weight of Nevro (NYSE:NVRO) stock in their portfolio include Alger Weatherbie Enduring Growth ETF (AWEG) and Fidelity Digital Health ETF (FDHT).iShares Neuroscience and Healthcare ETF (IBRN). What guidance has Nevro issued on next quarter's earnings? Nevro issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $435.0 million-$445.0 million, compared to the consensus revenue estimate of $441.0 million. What is D. Keith Grossman's approval rating as Nevro's CEO? 9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees. What other stocks do shareholders of Nevro own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG). Who are Nevro's major shareholders? Nevro's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Principal Financial Group Inc. (1.94%), Assenagon Asset Management S.A. (0.34%), Susquehanna Fundamental Investments LLC (0.27%), Swiss National Bank (0.18%), Blair William & Co. IL (0.14%) and BNP Paribas Financial Markets (0.14%). Insiders that own company stock include D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane and Shawn Mccormick. View institutional ownership trends. How do I buy shares of Nevro? Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NVRO) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersThis 1 Biotech Stock has been shocking the marketsHuge Alerts1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nevro Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
